Extracorporeal CO2 Removal Devices Market Size & Growth Forecast 2026–2035, By Segments (Product, Application, End-use, Access), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Market Size and Growth Outlook

Extracorporeal CO2 Removal Devices Market size was valued at USD 95.57 Million in 2025 and is anticipated to grow at a 7.3% CAGR from 2026 to 2035, attaining USD 193.34 Million by 2035. The industry revenue for 2026 is calculated at USD 101.67 million.

• Base Year Value (2025): USD 95.57 Million
• CAGR (2026-2035): 7.3%
• Forecast Year Value (2035): USD 193.34 Million
• Historical Data Period: 2022-2025
• Largest Region: North America
• Forecast Period: 2026-2035

Extracorporeal CO2 Removal Devices Market Intelligence Snapshot:

• Regional Market Dynamics:

  • North America leads due to advanced critical care infrastructure, high ICU capacity, and widespread availability of extracorporeal support technologies in hospitals.
  • Europe growth is driven by increasing adoption of less invasive respiratory support strategies and expanding ICU capabilities, supported by an 8.25% CAGR.

• Segment Momentum:

  • Extracorporeal CO2 Machines held a 55.02% share in 2025 because they serve as the core treatment platform, determining system functionality, workflow integration, monitoring, and overall clinical delivery.
  • Acute Respiratory Distress Syndrome (ARDS) is the fastest-growing application, driven by increasing use of advanced respiratory support in intensive care settings where conventional ventilation may be insufficient.

• Market Expansion Drivers:

  • Rising COPD and ARDS cases increasing demand for extracorporeal CO2 removal devices.
  • Advancements in ECMO-compatible membrane oxygenators improving ICU respiratory support efficiency.
  • Expanding use in lung transplantation and thoracic surgeries enhancing perioperative outcomes.

• Leading Market Participants:

  Major players in the extracorporeal CO2 removal devices market include Medtronic plc (Ireland), Getinge AB (Sweden), Xenios AG (Germany), Medica S.p.A. (Italy), Aferetica srl (Italy), ESTOR S.P.A. (Italy), Baxter International Inc. (United States), X-COR Therapeutics (United States), Fresenius Medical Care AG & Co. KGaA (Germany).

Unlock Complete Insights

Global Market Forecast Snapshot:

• Market Outlook:

  • 2025 Market Size: USD 95.57 Million
  • Projected Market Size: USD 193.34 Million by 2035
  • Growth Forecasts: 7.3% CAGR (2026-2035)

• Regional and Segment Outlook:

  • Leading Regional Market: North America
  • High-Growth Regional Hub: Europe
  • Core Revenue Segment: Extracorporeal CO2 Machines (Product) | Bridge to Lung Transplant (Application) | Hospitals (End-use) | Venovenous (Access)
  • Emerging Opportunity Segment: Disposables (Product) | Acute Respiratory Distress Syndrome (ARDS) (Application) | Hospitals (End-use) | Arteriovenous (Access)

Market Growth Drivers and Industry Trends

Rising COPD and ARDS cases increasing demand for extracorporeal CO2 removal devices

Growing incidence of COPD exacerbations and acute respiratory distress syndrome is pushing critical care teams to seek respiratory support options that control hypercapnia without escalating immediately to highly invasive ventilation strategies. In the extracorporeal CO2 removal devices market, this pattern is driving demand from ICUs managing patients who are difficult to ventilate safely, particularly where clinicians are trying to reduce ventilator-induced lung injury, shorten time on mechanical ventilation, or stabilize patients who are not responding adequately to conventional care. As these case loads rise, hospitals are more likely to evaluate ECCO2R systems as part of severe respiratory failure protocols, encouraging market growth through higher device utilization, procurement of compatible consumables, and broader incorporation into critical care pathways.

Advancements in ECMO-compatible membrane oxygenators improving ICU respiratory support efficiency

Improvements in ECMO-compatible membrane oxygenators are making extracorporeal CO2 removal systems easier to integrate into existing ICU workflows, which directly influences market adoption by reducing operational friction for hospitals already familiar with extracorporeal support platforms. In the extracorporeal CO2 removal devices market, better gas exchange performance, more efficient membrane design, and compatibility with established extracorporeal circuits help clinicians deliver targeted CO2 clearance with greater confidence in complex respiratory cases. This strengthens market development because purchasing decisions in critical care often favor technologies that fit current infrastructure, training models, and perfusion practices rather than requiring entirely separate systems or new clinical processes.

Expanding use in lung transplantation and thoracic surgeries enhancing perioperative outcomes

Use of extracorporeal CO2 removal in lung transplantation and thoracic surgery is increasing as surgical teams place greater emphasis on maintaining gas exchange stability while limiting the physiological strain associated with aggressive ventilation during and around procedures. For the extracorporeal CO2 removal devices market, this creates a distinct source of demand from transplant centers and high-acuity surgical programs that need perioperative respiratory support tools capable of managing hypercapnia in fragile patients. The effect is particularly meaningful because adoption in these settings tends to be protocol-driven and tied to specialized care pathways, reinforcing market demand through repeat use in complex procedures where clinicians are prioritizing smoother intraoperative management and postoperative recovery trajectories.

Growth Driver Assessment Framework
Growth Driver	Impact On CAGR	Regulatory Influence	Geographic Relevance	Adoption Rate	Impact Timeline
Rising COPD and ARDS cases increasing demand for extracorporeal CO2 removal devices	2.10%	High	North America, Europe	Emerging	Near Term
Advancements in ECMO-compatible membrane oxygenators improving ICU respiratory support efficiency	1.70%	High	North America, Europe	Medium	Mid Term
Expanding use in lung transplantation and thoracic surgeries enhancing perioperative outcomes	1.50%	High	Europe, North America	Medium	Mid Term

Regional Demand Dynamics

North America (Largest Region) vs Europe (Fastest-Growing Region)

North America held the largest regional share of the extracorporeal CO2 removal devices market in 2025, supported by the region’s advanced critical care infrastructure, broad availability of intensive care services, and established use of extracorporeal support technologies in hospital settings. The region’s leadership is aided by the concentration of specialized centers capable of managing severe respiratory failure, where adoption depends on trained multidisciplinary teams, continuous monitoring capacity, and access to high-acuity treatment pathways. These practical care-delivery advantages help sustain procedure volumes and support ongoing device utilization across major healthcare institutions.

Europe is projected to expand at an 8.25% CAGR over the forecast period, with growth in the extracorporeal CO2 removal devices market being propelled by increasing clinical focus on less invasive respiratory support strategies and broader integration of advanced critical care approaches across the region. Adoption is accelerating as hospitals strengthen capabilities for managing complex pulmonary and intensive care cases, creating a more favorable environment for extracorporeal CO2 removal in day-to-day clinical practice. The region’s growth momentum is also supported by rising familiarity among care teams with extracorporeal therapies, which improves confidence in patient selection and operational use within critical care workflows.

Regional Market Attractiveness & Strategic Fit Matrix
Parameter	North America	Asia Pacific	Europe	Latin America	MEA
Innovation Hub	Advanced	Developing	Advanced	Developing	Nascent
Cost-Sensitive Region	Low	Medium	Low	High	High
Regulatory Environment	Supportive	Neutral	Restrictive	Neutral	Neutral
Demand Drivers	Strong	Moderate	Strong	Moderate	Weak
Development Stage	Developed	Developing	Developed	Developing	Emerging
Adoption Rate	High	Medium	High	Medium	Low
New Entrants / Startups	Dense	Moderate	Dense	Sparse	Sparse
Macro Indicators	Strong	Stable	Stable	Weak	Weak

Key Country Insights

United States

Critical Care Innovation

The U.S. extracorporeal CO2 removal devices market is supported by advanced critical care facilities evaluating less invasive respiratory support technologies. Clinical adoption is driven by interest in expanding treatment options for patients with severe respiratory complications.

Japan

Precision Respiratory Care

Japan is exploring extracorporeal CO2 removal devices to strengthen advanced respiratory care in hospitals managing complex pulmonary conditions. Clinical attention is focused on technologies that support effective carbon dioxide removal with careful patient monitoring.

South Korea

Advanced ICU Integration

South Korea is incorporating extracorporeal CO2 removal devices into modern intensive care environments supported by expanding critical care capabilities. Hospitals are evaluating systems that complement existing respiratory treatment approaches and improve clinical workflow.

Germany

Hospital-Based Clinical Adoption

Germany is integrating extracorporeal CO2 removal devices into specialized intensive care settings where respiratory management protocols continue to evolve. Healthcare providers are assessing device performance alongside established extracorporeal treatment pathways.

France

Evidence-Driven Clinical Use

France is emphasizing clinically validated extracorporeal CO2 removal technologies for carefully selected respiratory care applications. Healthcare institutions are prioritizing devices that demonstrate practical integration with established intensive care practices.

Italy

Specialized Critical Care Access

Italy is expanding access to extracorporeal CO2 removal devices through specialized hospitals treating patients with complex respiratory conditions. Clinical priorities include effective integration into critical care pathways while supporting consistent treatment outcomes.

Segment Leadership and Growth Trends

  Product Segment Analysis: Extracorporeal CO2 Machines (Largest Segment) vs Disposables (Fastest-Growing Segment)

Within the extracorporeal CO2 removal devices market, Extracorporeal CO2 Machines accounted for a 55.02% share in 2025, making them the leading product segment. This leadership is maintained through the fact that the machine serves as the core operating platform in extracorporeal CO2 removal procedures, shaping system functionality, treatment control, and clinical integration. Hospitals and specialized care settings prioritize these capital systems because they determine compatibility with care workflows, monitoring requirements, and overall treatment delivery, which keeps machine demand anchored at the center of product purchasing decisions.

Disposables are emerging as the fastest-growing product segment in the extracorporeal CO2 removal devices market as procedure expansion directly increases recurring component consumption. Their growth is tied to practical usage patterns: every treatment cycle depends on single-use or limited-use consumable items, so rising clinical adoption translates into repeated purchasing demand rather than one-time installation. Compared with machines, disposables benefit more immediately from increases in patient throughput and utilization frequency, which gives this segment stronger growth momentum as extracorporeal CO2 removal moves into broader clinical use.

Application Segment Analysis: Bridge to Lung Transplant (Largest Segment) vs Acute Respiratory Distress Syndrome (ARDS) (Fastest-Growing Segment)

Bridge to Lung Transplant held a 41.98% share of the extracorporeal CO2 removal devices market in 2025, establishing it as the largest application segment. Its leading position is supported by the clear clinical role of extracorporeal CO2 removal in stabilizing patients awaiting transplant while helping manage respiratory burden during a highly critical treatment window. This application tends to involve closely monitored, high-acuity cases where extracorporeal support is integrated into specialized care pathways, sustaining demand through defined use in transplant-focused respiratory management.

Acute Respiratory Distress Syndrome (ARDS) represents the fastest-growing application in the extracorporeal CO2 removal devices market because it aligns with the need for advanced respiratory support in intensive care settings where conventional ventilation strategies may be insufficient on their own. Growth is being driven by the practical value of extracorporeal CO2 removal in managing severe gas-exchange impairment while supporting lung-protective treatment approaches. Relative to more established applications, ARDS is gaining momentum as clinicians evaluate extracorporeal support across a wider set of critically ill respiratory patients, expanding the use case for these devices.

Report Segmentation
Segment	Sub-Segment	Largest Segment	Fastest Growing Segment
Product	Extracorporeal CO2 Machines, Disposables, Others	Extracorporeal CO2 Machines	Disposables
Application	Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), Bridge to Lung Transplant, Others	Bridge to Lung Transplant	Acute Respiratory Distress Syndrome (ARDS)
End-use	Hospitals, Ambulatory Surgical Centers, Clinics, Others	Hospitals	Hospitals
Access	Venovenous, Arteriovenous	Venovenous	Arteriovenous

Competitive Landscape and Market Positioning

Prominent players in the extracorporeal CO2 removal devices market:

1. Medtronic plc (Ireland)

2. Getinge AB (Sweden)

3. Xenios AG (Germany)

4. Medica S.p.A. (Italy)

5. Aferetica srl (Italy)

6. ESTOR S.P.A. (Italy)

7. Baxter International Inc. (United States)

8. X-COR Therapeutics (United States)

9. Fresenius Medical Care AG & Co. KGaA (Germany)

The extracorporeal CO2 removal devices market is witnessing continuous innovation focused on compact system design, improved patient safety, and enhanced respiratory support efficiency. Investments in advanced membrane technologies and minimally invasive solutions are strengthening product differentiation while supporting broader clinical adoption in critical care settings.

Competitive Dynamics and Strategic Insights
Assessment Parameter	Assigned Scale	Scale Justification
Competitive Advantage Sustainability	Durable	Regulatory approvals and clinical efficacy, such as a 50% CO2 reduction in ARDS, ensure advantages.
Market Concentration	Medium	Led by ALung Technologies, Medtronic, and Getinge, but emerging players compete in niches.
M&A Activity / Consolidation Trend	Active	Acquisitions target compact and portable ECCO2R tech for critical care applications.
Degree of Product Differentiation	High	Diverse devices (portable, integrated with ECMO) for ARDS and COPD treatment.
Innovation Intensity	High	Advances in compact systems and biocompatible materials drive rapid innovation.
Customer Loyalty / Stickiness	Strong	Hospital contracts and proven outcomes in critical care foster high loyalty.
Vertical Integration Level	Medium	Firms develop devices but rely on external components and hospital distribution.

Industry Development/News

Company Name	Date	Key Development
LivaNova PLC	May-22	LivaNova PLC acquired ALung Technologies to integrate the Hemolung Respiratory Assist System into its clinical portfolio. This acquisition strengthens LivaNova’s position in the respiratory care segment by providing access to advanced extracorporeal CO2 removal technology, designed to serve as a viable alternative or adjunct to invasive mechanical ventilation.
ALung Technologies	Oct-22	ALung Technologies initiated clinical evaluations of its Hemolung Respiratory Assist System to assess its efficacy in delivering low-flow extracorporeal CO2 removal for patients experiencing acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD). This study aims to demonstrate the utility of the device in reducing reliance on traditional invasive mechanical ventilation.